Sygnature Discovery

Sygnature Discovery is a leading integrated drug discovery Contract Research Organisation, founded in 2004. With a diverse team of over 1000 staff from 53 nationalities, including 900 scientists, the company has made significant contributions to the field. Their track record boasts the delivery of over 40 pre-clinical compounds and 21 clinical compounds, with their scientists named on over 170 patent applications.

The company specializes in providing integrated drug discovery services, spanning from target identification to candidate nomination. They work in collaboration with global pharma, biotech, and NFP organizations. Sygnature Discovery's areas of expertise include protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases, and fibrotic diseases.

Operating in the Biotechnology industry, with its headquarters in the United Kingdom, Sygnature Discovery recently received a Secondary Market investment on 29 June 2021 from Five Arrows Principal Investments, signifying continued interest and support from notable investors.